Jennifer Butler, chief commercial officer of Pleio, discusses misinformation's threat to public health, where patients are ...

March is Colorectal Cancer Awareness Month, and the health plan hopes to improve survival rates with early screenings.

Sun Pharma’s acquisition of Checkpoint Therapeutics includes Unloxcyt, an FDA-approved anti-PD-L1 therapy for metastatic and ...

Aliya Omer, VP, US franchise head, breast cancer, AstraZeneca, discusses Lynparza’s role in reducing the risk of invasive disease recurrence or death in HR-positive breast cancer patients.

Five-year data from Phase III trials demonstrated that 67.7% of patients moderate-to-severe plaque psoriasis treated with UCB ...

Jonathon Whitton, AuD, PhD, VP, auditory global program head, Regeneron, discusses how key regulatory designations, such as the FDA's Regenerative Medicine Advanced Therapy designation, facilitate ...

HEOR scientists in the pharma industry must balance methodologic rigor with commercial expectations and timelines.

Artiva Biotherapeutics' CEO Fred Aslan, MD, discusses two ongoing trials for autoimmunity indications in the US and how AlloNK differs from traditional B-cell depletion strategies.

Clinical trial results found that a majority of patients with atopic dermatitis who were treated with Ebgylss achieved ...

The approval of neffy marks the first major advancement in epinephrine delivery for patients over four years of age in more ...

In the SWIFT and ANCHOR trials, depemokimab demonstrated statistically significant reductions in nasal polyp size, ...

The six key design trends of 2025 redefine how healthcare brands can inspire trust and build lasting connections with their ...